AZN's Antibody Authorized For COVID-19, RDUS Shrinks, ZYME On Watch, FDA Panel Snubs RETA

Today's Daily Dose brings you news about the first antibody therapy for the prevention of COVID-19, the FDA panel review of Reata Pharma's Alport syndrome drug; disappointing data from Radius Health's wearABLe study; and encouraging new data of Zymeworks' Zanidatamab in breast cancer.